SUPERNUS PHARMACEUTICALS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Income (Loss) from Continuing Operations, Per Diluted Share of $2.34 per share for the 3-month period ending 2011-12-31, per its 10-K filed 2013-03-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2013-03-15
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-12-31 was $2.34.
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-09-30 was -$6.90.
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-06-30 was -$6.15.
- SUPERNUS PHARMACEUTICALS, INC. income (loss) from continuing operations, per diluted share for the quarter ending 2011-03-31 was -$6.64.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month |
|---|---|
| 2011-12-31 | $2.34 10-K · filed 2013-03-15 |
| 2011-09-30 | -$6.90 10-K · filed 2013-03-15 |
| 2011-06-30 | -$6.15 10-K · filed 2013-03-15 |
| 2011-03-31 | -$6.64 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |